Health Care

European Medicines Agency validates Bristol Myers Squibb’s application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B Application based on positive results from TRANSCEND NHL 001 study and additional TRANSCEND WORLD 001 study PRINCETON, N.J.–(BUSINESS

Business

AM Best removes from under review with developing implications and affirms credit ratings of National Lloyds Insurance Company and American Summit Insurance Company

OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has removed from under review with developing implications and affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of “a” of National Lloyds Insurance Company (NLIC) and American Summit Insurance Company (ASIC), collectively

Business, Media & Communications

IEEE-ISTO Printer Working Group (PWG) announces updated Internet Printing Protocol (IPP) extensions to support additive manufacturing/3D Printing and a specification for Safe G-Code that avoids 3D printing commands with safety or security concerns

PISCATAWAY, N.J.–(BUSINESS WIRE)–The IEEE-ISTO Printer Working Group (PWG) has released IPP 3D Printing Extensions v1.1 (PWG 5100.21-2019) and PWG Safe G-Code Subset for 3D Printing v1.0 Best Practices (PWG 5199.7-2019). These documents build on previously defined extensions to the Internet Printing Protocol

Local News

Construction starts show additional gains in June

Improvement in nonresidential and nonbuilding activity push starts higher NEW JERSEY–(BUSINESS WIRE)–Total construction starts increased 6% in June to a seasonally adjusted annual rate of $641.4 billion. This marks the second consecutive monthly gain in construction starts following the COVID-19 induced declines

Business, Health Care

Humanigen expands partnership with Catalent biologics to manufacture investigational COVID-19 therapeutic candidate lenzilumab

Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent’s OneBio® integrated biologics suite expected to accelerate development, manufacturing and supply of